THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that a Type B meeting has been scheduled with the Food and Drug Administration (“FDA”) for November 30, 2007. The purpose of the meeting is to review results from the clinical trials of Proellex® conducted to date and to discuss the initiation of Phase 3 studies. Repros also plans to discuss the potential of conducting clinical trials for a new indication for the treatment of anemia associated with excessive menstrual bleeding.
